Monitoring and Management of Patients on Therapy for Chronic Hepatitis B
Last updated: December 10, 2009
A 38-year-old Vietnamese man with chronic hepatitis B infection comes to you for follow-up. His past laboratory studies show positive hepatitis B e antigen (HBeAg), negative hepatitis B e antibody (anti-HBe), HBV DNA level of 108 IU/ml, and an alanine aminotransferase (ALT) between 30 to 40 U/L over a period of 12 months. A liver biopsy shows grade 3 inflammation and stage 2 fibrosis. He is started on entecavir (Baraclude).
Which of the following statements is TRUE regarding recommendations from the American Association for the Study of Liver Diseases (AASLD) regarding monitoring and management of patients on therapy for chronic hepatitis B?